Christopher Morgan, MD
Family Medicine · Stuttgart, ARNPI 1255397006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $277 and has fallen 54.4% since, to $126 in 2025.
Across 76 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$219
- Novo Nordisk$117
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98
- Amgen$89
- Pfizer$89
- AbbVie$89
- plus $461 from 17 others
What the payments were for
- Food & beverage$1,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $219 |
| Novo Nordisk | 8 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $98 |
| Amgen | 6 | $89 |
| Pfizer | 7 | $89 |
| AbbVie(2 entities) | 5 | $89 |
| Merck | 5 | $89 |
| AstraZeneca | 4 | $72 |
| Merz North America, Inc. | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $24 |
| Novartis | 2 | $24 |
| Corium, LLC | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Boston Scientific | 1 | $12 |
How this compares
$1,162 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 766 | $237,258 |
| XareltoRivaroxaban | 410 | $159,195 |
| JardianceEmpagliflozin | 287 | $153,920 |
| OzempicSemaglutide | 114 | $107,840 |
| EntrestoSacubitril/Valsartan | 171 | $52,626 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $46,293 |
| JanuviaSitagliptin Phosphate | 164 | $44,893 |
| XifaxanRifaximin | 32 | $34,048 |
| AptiomEslicarbazepine Acetate | 47 | $33,689 |
| Spiriva RespimatTiotropium Bromide | 34 | $26,705 |
| LinzessLinaclotide | 43 | $23,895 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 74 | $23,684 |
| TrulicityDulaglutide | 23 | $23,052 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $22,619 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $22,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $89 | $237,258766 claims |
| Johnson & JohnsonXarelto | $24 | $159,195410 claims |
| Novo NordiskOzempic | $117 | $107,840114 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Lokelma, Symbicort | $72 | $57,828131 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $219 | $53,090103 claims |
| NovartisEntresto | $24 | $52,626171 claims |
| MerckJanuvia | $89 | $44,893164 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $98 | $34,04832 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $14 | $33,68947 claims |
| AbbVieLinzess | $89 | $23,89543 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $12,08248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Stuttgart
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
- Harold BettonLittle Rock$18K
- Thad HardinConway$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.